Key result
Direct oral anticoagulants significantly lowered the risk of stroke or systemic embolism compared to vitamin K antagonists (HR 0.81; 95% CI 0.70-0.93; P=0.002) in AF patients with kidney disease.
Why the study?
The efficacy of direct oral anticoagulants versus vitamin K antagonists in patients with AF and CKD, ESRD, or undergoing hemodialysis needed evaluation.
Do DOACs reduce stroke or systemic embolism in adult patients with atrial fibrillation and chronic kidney disease, end-stage renal disease, or on hemodialysis compared to vitamin K antagonists?
Meta-Analysis (n=178,956)
Do DOACs reduce stroke or systemic embolism in adult patients with atrial fibrillation and chronic kidney disease, end-stage renal disease, or on hemodialysis compared to vitamin K antagonists?
Hazard Ratio: 0.81 (95% CI 0.7–0.93)
p-value: p=0.002
In patients with atrial fibrillation and kidney disease (including ESRD and hemodialysis), DOACs are associated with a significantly lower risk of stroke, systemic embolism, and bleeding compared to vitamin K antagonists.
Supports DOAC preference in AF with CKD/ESRD; reinforces evidence from general populations to renal impairment.
INTRODUCTION: This meta-analysis seeks to evaluate the efficacy of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) in individuals with chronic kidney disease (CKD), end-stage renal disease (ESRD), and undergoing hemodialysis (HD) who also have atrial fibrillation (AF).EVIDENCE ACQUISITION: A comprehensive search of MEDLINE, clinicaltrials.gov, EMBASE, and Cochrane Database for relevant studies reporting the usefulness of OAC therapy for CKD, ESRD, and HD patients with AF was conducted from its inception until 1st May 2023. The studies that reported OR, RR, or HR for adult AF patients to investigate the efficacy of OAC in CKD, ESRD, and HD were included. Statistical analysis was completed using a generic inverse variance and random-effects model to calculate the combined HR and their corresponding 95% CIs for all outcomes.EVIDENCE SYNTHESIS: The meta-analysis included 33 studies with 178,956 patients. The analysis revealed that the DOACs, when compared to VKA, significantly lowered the risk of stroke or systemic embolism (HR: 0.81 [95% CI: 0.70, 0.93]; P=0.002; I2=62%), bleeding (HR: 0.77, [95% CI: 0.67, 0.89]; P=0.0003; I2=83%), and intracranial hemorrhage (HR: 0.56, [95% CI 0.47, 0.66]; P<0.00001; I2=0%). Similarly, the risks of cardiovascular death (HR: 0.88, [95% CI 0.78, 1.00]; P=0.05; I2=0%), all-cause mortality (HR: 0.88, [95% CI 0.70, 1.10]; P=0.25; I2=96%), and myocardial infarction (HR: 0.80, [95% CI 0.54, 1.17]; P= 0.25; I2= 0%) were lowered by DOAC, but the result was insignificant. No significant difference was seen in the risk of gastrointestinal bleeding between DOAC and VKA as well (HR: 0.95, [95% CI 0.75, 1.20]; P=0.65; I2=83%).CONCLUSIONS: Our meta-analysis confirms that DOACs are effective for managing AF in patients with kidney disease, with potential clinical implications for AF and CKD management. Further research should explore DOACs’ reno-protective effects.
No takes yet. Share an insight, caveat, or question.
Latif et al. (2024) conducted a meta-analysis in Atrial fibrillation with chronic kidney disease, end-stage renal disease, or hemodialysis (n=178,956). Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKA) was evaluated on Stroke or systemic embolism (HR 0.81, 95% CI 0.70, 0.93, p=0.002). Direct oral anticoagulants significantly lowered the risk of stroke or systemic embolism compared to vitamin K antagonists (HR 0.81; 95% CI 0.70-0.93; P=0.002) in AF patients with kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: